Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Novartis wades into stem cell therapies

Novartis will pay $35 million for a 15% stake in Gamida Cell, with an option to buy the Jerusalem–based stem cell developer in the next few years. Gamida's lead product NiCord is currently in phase 1/2 to treat patients suffering from leukemia, lymphoma and sickle cell disease. NiCord is CD133+ hematopoietic stem cells within a unit of cord blood expanded with nicotinamide (vitamin B3) over a period of 21 days. Should Novartis exercise its option based on development and regulatory milestones, the Swiss drug maker will pay Gamida shareholders $165 million in cash, with potential future payments reaching another $435 million based on sales.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Novartis wades into stem cell therapies. Nat Biotechnol 32, 969 (2014). https://doi.org/10.1038/nbt1014-969e

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing